Akarx Patent-Cliff Exposure & CMS Drug Spending Portfolio

Akarx (US): 2 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $196.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$196.1M
2024 Medicare Part D Spend$159.7M
2024 Medicaid Spend$36.4M
California HCAI SB 17 Filings6 WAC filings (max 20.1% 2-yr change)